Curaleaf Holdings Dirección

Dirección controles de criterios 3/4

El CEO de Curaleaf Holdings' es Matt Darin , nombrado en May 2022, tiene una permanencia de 1.92 años. compensación anual total es $1.06M, compuesta por 64.5% salario y 35.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.58% de las acciones de la empresa, por valor de CA$27.56M. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 4.8 años, respectivamente.

Información clave

Matt Darin

Chief Executive Officer (CEO)

US$1.1m

Compensación total

Porcentaje del salario del CEO	64.5%
Permanencia del CEO	1.9yrs
Participación del CEO	0.6%
Permanencia media de la dirección	3.3yrs
Promedio de permanencia en la Junta Directiva	4.8yrs

Actualizaciones recientes de la dirección

Recent updates

Subdued Growth No Barrier To Curaleaf Holdings, Inc. (TSE:CURA) With Shares Advancing 25%

Jan 19

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Matt Darin en comparación con los beneficios de Curaleaf Holdings?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$230m
Sep 30 2023	n/a	n/a	-US$457m
Jun 30 2023	n/a	n/a	-US$426m
Mar 31 2023	n/a	n/a	-US$382m
Dec 31 2022	US$1m	US$683k	-US$258m
Sep 30 2022	n/a	n/a	-US$157m
Jun 30 2022	n/a	n/a	-US$202m
Mar 31 2022	n/a	n/a	-US$223m
Dec 31 2021	US$463k	US$350k	-US$206m

Compensación vs. Mercado: La compensación total de Matt($USD1.06M) está por debajo de la media de empresas de tamaño similar en el mercado Canadian ($USD3.54M).

Compensación vs. Ingresos: La compensación de Matt ha aumentado mientras la empresa no es rentable.

CEO

Matt Darin

1.9yrs

Permanencia

US$1,058,651

Compensación

Mr. Matthew S. Darin, also known as Matt, serves as President and Director at Curaleaf, Inc. He served as President of Curaleaf Holdings, Inc since January 04, 2022 until May 09, 2022 and serves as Chief E...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Boris Jordan	Executive Chairman	5.5yrs	US$1.75m	4.96% $ 316.1m
Matthew Darin	Chief Executive Officer	1.9yrs	US$1.06m	0.58% $ 36.7m
Joseph Lusardi	Executive Vice-Chairman	5.5yrs	US$657.70k	0.72% $ 45.8m
Edward Kremer	Chief Financial Officer	1.7yrs	US$461.74k	0.027% $ 1.7m
Camilo Lyon	Chief Investment Officer	1.7yrs	sin datos	sin datos
Jakob Feinstein	Manager of Investor Relations	no data	sin datos	sin datos
Peter Clateman	Chief Legal Officer	4.3yrs	sin datos	0.11% $ 6.9m
James Shorris	Chief Compliance Officer	4.1yrs	sin datos	sin datos
Tracy Brady	Senior Vice President of Corporate Communications	4.3yrs	sin datos	sin datos
Kate Lynch	Executive Vice President of Marketing	3.3yrs	sin datos	sin datos
Tyneeha Rivers	Chief People Officer	1.9yrs	sin datos	sin datos
Jessie Kater	Senior Vice President of Innovation	no data	sin datos	sin datos

3.3yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CURA se considera experimentado (3.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Boris Jordan	Executive Chairman	5.5yrs	US$1.75m	4.96% $ 316.1m
Joseph Lusardi	Executive Vice-Chairman	5.5yrs	US$657.70k	0.72% $ 45.8m
Mitchell Kahn	Director	3.8yrs	US$195.03k	0.52% $ 32.9m
Peter Derby	Independent Director	5.5yrs	US$345.50k	0.070% $ 4.4m
Karl Johansson	Independent Director	5.5yrs	US$345.50k	0.013% $ 829.8k
Robert Schnoll	Member of the Medical Advisory Board	no data	sin datos	sin datos
Jaswinder Grover	Independent Director	4.2yrs	US$133.33k	0.75% $ 47.8m
Michelle Bodner	Director	1.3yrs	US$230.78k	0.034% $ 2.1m
Shasheen Shah	Independent Director	1.3yrs	US$79.38k	0.0028% $ 179.2k

4.8yrs

Permanencia media

59.5yo

Promedio de edad

Junta con experiencia: La junta directiva de CURA se considera experimentada (4.8 años de antigüedad promedio).

Curaleaf Holdings Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Curaleaf Holdings, Inc., Annual General Meeting, Jun 14, 2024

Executive Vice-Chairman recently sold CA$860k worth of stock

Curaleaf Holdings, Inc., Annual General Meeting, Oct 04, 2023

Less than half of directors are independent

Less than half of directors are independent

Executive Vice-Chairman recently sold CA$160k worth of stock

Recent updates

Curaleaf Holdings, Inc. (TSX:CURA) completed the acquisition of Northern Green Canada Inc. (NGC).

Curaleaf Holdings, Inc., Annual General Meeting, Jun 14, 2024

Curaleaf Holdings, Inc. to Report Q1, 2024 Results on May 09, 2024

Curaleaf Holdings, Inc. (TSX:CURA) signed a deal to acquire Northern Green Canada Inc. (NGC).

Subdued Growth No Barrier To Curaleaf Holdings, Inc. (TSE:CURA) With Shares Advancing 25%

Curaleaf Expands Zero Proof™ Brand Portfolio with Launch of Stir Fast-Acting THC Beverage Mix

Does Curaleaf Holdings (CSE:CURA) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 36%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Curaleaf Holdings, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Executive Vice-Chairman recently sold CA$860k worth of stock

Is Curaleaf Holdings (CSE:CURA) Using Too Much Debt?

Curaleaf Expands Brand Portfolio with Launch of Zero Proof ™ Cannabis-Infused Drinkables

Curaleaf Holdings, Inc., Annual General Meeting, Oct 04, 2023

Curaleaf Holdings, Inc.'s Select™ Brand Expands Product Offerings With Launch of Select Liquid Diamonds

Second quarter 2023 earnings: EPS misses analyst expectations

Curaleaf Holdings, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Curaleaf Holdings, Inc. Unveils Strategic National Rebrand of Select

New minor risk - Shareholder dilution

Curaleaf Holdings (CSE:CURA) Has Debt But No Earnings; Should You Worry?

Consensus EPS estimates fall by 66%

Forecast breakeven date moved forward to 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Less than half of directors are independent

Curaleaf Holdings, Inc. Announces Closure of Operations in California, Colorado and Oregon

Forecast to breakeven in 2025

Less than half of directors are independent

Curaleaf Holdings, Inc. Announces Expansion of BlueKudu Infused Chocolate Flavors Available on Florida Retail Menus

Curaleaf Holdings, Inc. Announces the Launch of Adult-Use Sales At Its Bordentown, New Jersey Location

Curaleaf Holdings Relocates Deerfield, IL Dispensary and Opens Doors to Adult-Use Customers

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) completed the acquisition of Tryke Companies, LLC for approximately $180 million.

Executive Vice-Chairman recently sold CA$160k worth of stock

We Think Curaleaf Holdings (CSE:CURA) Is Taking Some Risk With Its Debt

No longer forecast to breakeven

Consensus EPS estimates fall by 42%

No longer forecast to breakeven

Curaleaf Holdings, Inc., Annual General Meeting, Sep 08, 2022

Curaleaf Holdings, Inc. Announces Management Appointments

Curaleaf Holdings, Inc. Launches Plant Precision, New Product Line Targeting Specific Health and Wellness Categories

Consensus forecasts updated

Curaleaf Holdings, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Curaleaf Expands New Jersey Adult-Use Sales to Edgewater Park Dispensary

Curaleaf Expands New Jersey Adult-Use Sales to Edgewater Park Dispensary

Here's Why Curaleaf Holdings (CSE:CURA) Has A Meaningful Debt Burden

First quarter 2022 earnings: EPS exceeds analyst expectations

Curaleaf Holdings, Inc. Reports Impairment Loss for the Quarter Ended March 21, 2022

Curaleaf Holdings, Inc. Announces Executive Changes

Consensus forecasts updated

Forecast breakeven date pushed back to 2023

Curaleaf Holdings, Inc Expands Product Offerings With Launch of BlueKudu Chocolates in Florida

Curaleaf Holdings, Inc., Annual General Meeting, Jun 23, 2022

Curaleaf Holdings, Inc. Announces its Select Brand Launches Limited-Edition Cliq Elite Live Strain in California

Curaleaf Holdings, Inc. to Report Q1, 2022 Results on May 09, 2022

Interim Chief Financial Officer exercised options to buy CA$851k worth of stock.

Curaleaf Holdings, Inc. Reports Impairment of Intangible Assets for the Fourth Quarter Ended December 31, 2021

Full year 2021 earnings: EPS exceeds analyst expectations

Curaleaf Holdings, Inc. (CNSX:CURA) completed the acquisition of Bloom Dispensaries.

Curaleaf Holdings, Inc. (CNSX:CURA) entered into a definitive agreement to acquire Bloom Dispensaries for approximately $210 million.

Curaleaf Holdings, Inc. (CNSX:CURA) agreed to acquire Natural Remedy Patient Center, LLC for $13 million.

Curaleaf Holdings, Inc. announced that it has received $475 million in funding

Curaleaf Holdings, Inc. Launches Select X Bites

Third quarter 2021 earnings released: US$0.081 loss per share (vs US$0.015 loss in 3Q 2020)

Is Curaleaf Holdings (CSE:CURA) A Risky Investment?

Director recently sold CA$1.4m worth of stock

Curaleaf Holdings, Inc. Announces the Release of Cliq by Select

Second quarter 2021 earnings released

Curaleaf Holdings, Inc. (CNSX:CURA) signed definitive documents to acquire Los Sueños Farms LLC for $75 million.

Curaleaf Holdings, Inc. Provides Revenue Guidance for the Second Quarter of 2021

PharmaCann Inc. acquired Elevate Takoma dispensary from Curaleaf Holdings, Inc. (CNSX:CURA).